Biotecnologicas

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8966
Registrado: 09 May 2012 01:38

Re: Biotecnologicas

Mensajepor Dalamar » 23 Nov 2012 17:02

Shares of Star Scientific (STSI +10.2%) roar higher with the company's cash situation still a source of intense debate. A $20M capital infusion by a group of shareholders is either a finger in the dike or a rallying point depending upon a trader's point of view.
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8966
Registrado: 09 May 2012 01:38

Re: Biotecnologicas

Mensajepor Dalamar » 18 Dic 2012 06:37

El empresario José Manuel Lara Bosch ha adquirido el 30% de la biotecnológica catalana Plasmia Biotech, con lo que se ha convertido en su máximo accionista, ha informado la compañía especializada en el desarrollo de materias primas de antivirales y antitumorales utilizando la síntesis enzimática de análogos nucleosídicos.

En un comunicado, ha destacado que la entrada del presidente del Grupo Planeta en el accionariado y el consejo de administración de Plasmia Biotech ha supuesto “un paso adelante para el desarrollo del plan de negocio”.

La empresa biotecnológica fue constituida en 2010 para explotar una plataforma tecnológica que permite una mejora en los procesos de descubrimiento y de síntesis de un grupo determinado de moléculas, los análogos nucleosídicos, mediante ingeniería genética.

Plasmia Biotech ha iniciado la patente de tres nuevos fármacos con “prometedora actividad” en cáncer de mama y próstata como resultado de un proyecto Eurostars, consolidando una nueva línea de negocio para el desarrollo de nuevos fármacos antitumorales.

Los objetivos a corto plazo de la empresa se centran el en desarrollo de procesos de producción de fármacos ya existentes con ventajas en coste, plazos y seguridad, así como con un menor impacto ambiental, con el fin de cederlos a compañías interesadas en su comercialización.


Visto en GurusBlog
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8966
Registrado: 09 May 2012 01:38

Re: Biotecnologicas

Mensajepor Dalamar » 14 Ene 2013 10:34

The totality of this newly reported research on human subjects with active autoimmune thyroid inflammation demonstrates the ability of anatabine to throttle back only the harmful immune system components of inflammation without destructive immune system suppression. This is a quantum leap forward and a breakthrough of historic proportions in the treatment of inflammatory auto-immune thyroid conditions.

Importantly, autoimmune diseases of the thyroid are but one of a near one hundred autoimmune conditions where current treatment consists of treating the symptoms rather than the illness itself. The potential for further anatabine studies on these conditions is near absolute. And because anatabine has been found to be safe, one can expect that many people who suffer from these conditions, and they are in the multimillions, will avail themselves of anatabine / Anatabloc.

Star Scientific currently has three active clinical trials on human subjects evaluating the safety and efficacy of Anatabloc on medical conditions driven by inflammatory components. The studies, being conducted in collaboration with both the Johns Hopkins University School of Medicine and the Roskamp Institute, include trials on Alzheimer's disease, autoimmune thyroiditis (Hashimoto's disease), and generalized systemic inflammation.

In a series of press releases in October, Star Scientific announced interim results from one of their anatabine clinical trials, the FLINT study (NCT01607619). This study was designed to measure the reduction of C-reactive protein (CRP) levels in human subjects with elevated CRP levels. An independent committee from the Roskamp Institute found that Anatabloc was safe and well tolerated, but more importantly, that the drug effected a decrease in C-reactive protein levels in a large percentage of the study population after only one month of dosing at the 1 mg dose, a very low dosage. Especially striking was the effect among diabetic patients, where a drop in CRP levels was observed in 61% of the participants. The word "safe" is important because an enormous number of drug candidates fail for safety concerns, e.g. Vioxx. One advantage of anatabine is that it is a natural component of common foods.

CRP is an important biomarker for inflammation and autoimmune conditions, and its elevation is associated with many debilitating diseases such as rheumatoid arthritis, autoimmune thyroiditis, ulcerative colitis, Crohn's disease, Lupus, multiple sclerosis, and many others. For a more comprehensive list, see here.

And finally, referencing the provisional patent application WO 2011/119722 A2 discloses that "S- (-) - anatabine positively correlates with reduction of the inflammatory activity."
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8966
Registrado: 09 May 2012 01:38

Re: Biotecnologicas

Mensajepor Dalamar » 19 Ene 2013 18:32

What is not well known in the civilian world, but well known in the scientific community, is that many Big Pharmas are eagerly pursuing research on both anabasine (the analog of anatabine) and alpha-7 nicotinic receptor agonists, which is what anatabine is. Because of the huge market potential, companies such as Pfizer (PFE), Abbott (ABT), Novartis (NVS), Lilly (LLY), Roche (RHHBY.OB), etc. are spending $billions in the hunt. These companies all have published papers or initiated clinical trials for alpha-7 agonists. For interesting detail on alpha-7 agonists from the National Institutes of Health, see the National Library of Medicine link here.

There is more. A peer review by the European Journal of Pharmacology of some recent Roskamp Institute studies titled Anti-inflammatory activity of anatabine via inhibition of STAT3 phosphorylation, which emphasizes the JAK-STAT signaling pathway acting on the same biochemical pathway as anatabine but considered safer than Tofacitinib, could have another level of positive implications for Star's compound Anatabloc[TRADE MARK SIGN]. Pharma, Big and small is also spending more $billions working in the JAK/STAT area - where more $billions in sales is their target: Pfizer, Lilly, J&J, Vertex, YM Biosciences, and Galapagos.

As followers of the Star science so well understand, we now know that Anatabine / Anatabloc lowers CRP and TNF-alpha in humans. There's a flourishing market out there for (TNF-αlpha) suppression drugs that is at least $22 billion per year (Remicade, Simponi, Humira, Enbrel, etc.). Johnson & Johnson (JNJ) brings in around $8 billion per year from this market alone! Also, know that there are lots of deleterious side effects for these drugs.

Pharma knows all about this testing of anatabine and the successful human trial results will free them to pursue a whole new thrust of interest in anatabine and bring about a new level of human testing on a multitude of fronts / illnesses. When you add up the totality of the Pharma interest and the mega $billions being spent by the industry in areas front and center to anatabine that I've documented above… you get the picture: Star's anatabine compound Anatabloc is in the catbird seat of a confluence of research that adds a quite mind-boggling multiplier in gauging its and the company's potential.

It becomes more than conceivable therefore that a small-cap like Star, with an effective and safe agent / compound, could be a buyout target; the possibility of an eventual bidding war exists.

Important for investors in Star shares is that these successful human trial results will allow a whole new group of institutional investors who previously were not able to invest in companies that did not have successful human trial to do so.

Additionally, the successful human studies will bring new analysis from the investment banking community and other financial writers and analysts who comment on companies and markets.

Furthermore, successful human trials now open the door for major media coverage. It's only a matter of time before we see an escalation in coverage of this story, perhaps highlighting some of the people who have been so helped by anatabine, as the testimonial on a CBS news affiliate that I have linked below demonstrates. To this point, the thousands of personal testimonials were only anecdotal. Suddenly, the playing field looks to be favorably tilted in Star's favor because its compound Anatabloc works on humans. The "man in the street interest" will compound and drive this interesting story. Media will grasp the compelling weight of this narrative and follow with enlarged coverage.

View a CBS news affiliate WNEM-TV video about Anatabloc[TRADE MARK SIGN] and inflammation as shown in the Flint/Tri-Cities market in Michigan that features Dale Wilson MD, one of the principal investigators in the clinical trial being conducted in the Flint area. In the video Dr. Wilson states that, "Anatabloc[TRADE MARK SIGN] turns chronic low grade inflammation off."

Perhaps even more relevant going forward, at least as far as a sudden monetizing event, would be that the just completed successful human trials will now allow Star to work out a licensing agreement with Pharma. Star has been working with McColl Partners LLC on "structuring a controlled auction for bidding by pharmaceutical companies, for licensing, and/or co-venturing relationships," and the successful human trial results may well authenticate the science with proof of concept and efficacy qualifiers, sweetening the deal by orders of magnitude. McColl Partners is an independent investment banking firm co-founded by Hugh McColl, former Chairman of Bank of America.

And… Fini

Institutional ownership of Star is at a new high

· 29,551,607 shares held by 118 institutions (less than 5% holders). A new high (20.2% of shares). For detail link Nasdaq here.

· 21,825,492 shares held by TradeWinds Investment, a "Beneficial Owner" of more than 5% (15.9% of shares) [SEC PRE14A]; that number is down from 23,231,111 shares, reportedly due to redemptions. Link EdgarOnline here.

• In a new filing [SEC 13G], 13,673,454 shares are held by John McKeon (8.2% of shares).

• In addition, all directors and executive officers as a group own 28,383,173 shares (17.5% of shares).

Thus; institutions, insiders and executive officers, plus a new 13G (passive) now hold a total of 93,433,726 shares - a new high by my counting. As a group they own roughly 60% of the shares.

The Short position has decreased about 11%

Over the last three reporting periods, the short interest has declined from 31,105,510 shares to 27,703,666 shares. This 3,401,844 share reduction represents a noteworthy percentile reversal of a several year increase of the short position. See link for full Nasdaq recap of the short position in Star shares.
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8966
Registrado: 09 May 2012 01:38

Re: Biotecnologicas

Mensajepor Dalamar » 23 Ene 2013 20:30

Shares of Star Scientific (STSI -11.9%) crumble after the company is taken to task over allegedly misleading investors over its relationship with Johns Hopkins University. Despite claims to the contrary, the academic institution doesn't have any official involvement with Star Scientific or nutritional supplement anatabine, according to Adam Feuerstein.
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8966
Registrado: 09 May 2012 01:38

Re: Biotecnologicas

Mensajepor Dalamar » 28 Ene 2013 14:00

One of the main problems with Alzheimer's is that the disease allows the brain to get soaked with a toxic molecule known as amyloid beta.

This overwhelms the nervous system's defenders, which are microglial cells. Because those cells can't get rid of amyloid beta, the brain builds up deposits called "senile plaques."

Spanning 12 weeks of research, team members gave weekly shots to mice with Alzheimer's symptoms. Here's the amazing thing: After the mice got the treatments, 80% of their senile plaques were gone.

Then the mice got tested on how well they could learn new tasks. Over that same three-month period, the mice showed marked improvement in their ability to think clearly.

Besides using MPL as a vaccine to stop Alzheimer's, the Laval-GSK team sees it as a possible treatment for those who already have the deadly brain disease. In that type of situation, patients would get a shot in one of their muscles so the compound could take root in the body and slow the disease down.

Once investors really assess what's in play here, I believe they'll take a closer look at GSK shares.

Don't let them the masses get the jump on you: GSK currently has a market cap of about $108 billion, and the company's shares are trading at roughly $44 each. With a consensus target of nearly $50 (about 13% above Friday's close) - and a hefty yield of 5.3% - you'll be well-compensated for your patience.

And the Alzheimer's drug could provide one heck of a subsequent tailwind ...

Let me close by noting that this is the second promising Alzheimer's treatment from Big Pharma in the last few months. I recently told you about how Baxter International Inc. (NYSE: BAX) had made progress with Gammagard, a drug given to patients intravenously.

Baxter says that four patients who received its new drug in trials showed no decline in memory or thinking skills. The drug contains antibodies that may help remove amyloid, says Baxter, which plans to test the treatment on 400 patients ... perhaps by the end of this year.
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8966
Registrado: 09 May 2012 01:38

Re: Biotecnologicas

Mensajepor Dalamar » 17 Feb 2013 14:07

Temas

Ciencias (general)

"En los últimos años estamos aprendiendo que hay un nuevo canal de comunicación para personas que lo han perdido y estamos tratando de aprovecharlo". Javier Mínguez, del Instituto de Investigación en Ingeniería de Aragón, es uno de los investigadores punteros en materia de interfaz cerebro-computador. Su trabajo consiste en traducir las señales del cerebro en impulsos reales que faciliten la vida a personas que han perdido la movilidad. "Se trata de personas que pierden el control sobre los músculos de su cuerpo y en algunos casos solo les queda el pensamiento", asegura.

"Lo básico es un dispositivo que lea la actividad cerebral", explica Mínguez. Lo más eficaz es el tradicional electroencefalograma (EGG) que registra la actividad eléctrica del cerebro de manera casi inmediata. Una vez registrada la señal "se utilizan unas potentes herramientas que decodifican algunos tipos de pensamientos".

Pero ¿cómo consiguen los científicos desentrañar nuestro pensamiento? Existen varios tipos de señales que emite nuestro cerebro y que saben reconocer. Los potenciales evocados, por ejemplo, saltan en el registro cuando se produce determinada actividad. Una señal muy conocida es P300. Simplificando mucho, podemos decir que esta señal salta cuando reconocemos una "diana".

"Si te digo que pienses en una carta", explica Mínguez, "y te las voy enseñando, cuando sale tu carta se dispara la P300". Y queda constancia en el encefalograma. Los sistemas que escriben con el pensamiento, por ejemplo, funcionan con un sistema similar. Van pasando letras por la pantalla y el software detecta el potencial P300 que se desata cuando el sujeto reconoce la letra en la que está pensando.

"Veremos en un futuro prótesis controladas por el pensamiento", asegura Mínguez, quien cree que las tecnologías no-invasivas utilizadas en Europa tienen un futuro prometedor. Al otro lado del Atlántico, las investigaciones van por el lado de prótesis invasivas, como las del investigador Miguel Nicolelis, que ya ha conseguido buenos resultados con macacos y trata de probarlo en humanos.

Mínguez y su equipo han desarrollado varias sillas de ruedas y un brazo robótico que se mueven por el pensamiento. El método consiste en interpretar las señales características que "emite" el cerebro" ante determinados estímulos. Si el sujeto piensa en moverse hacia la derecha, por ejemplo, el electroencefalograma y el software detectan la señal y dirigen la silla en la dirección elegida. Y esto es solo el principio de una gran revolución.


En "el mal del cerebro!"
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8966
Registrado: 09 May 2012 01:38

Re: Biotecnologicas

Mensajepor Dalamar » 02 Mar 2013 10:32

Mauldin dice:

I have been told that in a few weeks or months I am going to be one of the first to receive a new type of genetic analysis. Rather cutting-edge, it will tell me a great deal about my genetic predispositions and tie them into the latest research. I am not sure of the cost (it will not be cheap), but in a few years it will be standard procedure for those who want it and reasonably affordable, as it is one of those things that can be computerized.

In a few months, I will know of a lot of my potential pre-existing conditions. What if my insurer also eventually knows them? Do we work together to prevent a problem before it happens, or will they dump me or limit coverage?
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8966
Registrado: 09 May 2012 01:38

Re: Biotecnologicas

Mensajepor Dalamar » 05 Mar 2013 14:35

This company’s breakthrough is amazing…

It’s developed a proprietary system for something called "chemosaturation.” More than a drug, it’s a device. It’s a means of administering a high dose of chemotherapy directly into a diseased organ.

The system is complicated, of course. But essentially it involves saturating the tumor with a chemotherapy medication. But that’s not all. It minimizes (and even prevents) the usual side effects by filtering the powerful drugs out of the bloodstream before they can be circulated to otherparts of the body.

Folks, this is a system that:

Walls off and isolates deadly tumors…
Saturates and destroys them with ultra-heavy doses of lethal chemo…
Then, at the same time... miraculously “filters and purifies” the surrounding blood… completely eliminating the poison.

For millions of suffering people, this system stands to be a miracle – sheltering them from highly invasive surgery and debilitating and painful side effects… while giving them a better chance to survive.
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8966
Registrado: 09 May 2012 01:38

Re: Biotecnologicas

Mensajepor Dalamar » 13 Mar 2013 05:22

Antibiotic resistance poses a catastrophic threat to medicine and could mean patients having minor surgery risk dying from infections that can no longer be treated, Britain’s top health official said on Monday.

Sally Davies, the chief medical officer for England, said global action is needed to fight antibiotic, or antimicrobial, resistance and fill a drug “discovery void” by researching and developing new medicines to treat emerging, mutating infections.

Only a handful of new antibiotics have been developed and brought to market in the past few decades, and it is a race against time to find more, as bacterial infections increasingly evolve into “superbugs” resistant to existing drugs.

“Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics,” Davies told reporters as she published a report on infectious disease.

“And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.”

One of the best known superbugs, MRSA, is alone estimated to kill around 19,000 people every year in the United States – far more than HIV and AIDS – and a similar number in Europe.

And others are spreading. Cases of totally drug resistant tuberculosis have appeared in recent years and a new wave of “super superbugs” with a mutation called NDM 1, which first emerged in India, has now turned up all over the world, from Britain to New Zealand.

Last year the WHO said untreatable superbug strains of gonorrhoea were spreading across the world.

Laura Piddock, a professor of microbiology at Birmingham University and director of the campaign group Antibiotic Action, welcomed Davies’ efforts to raise awareness of the problem.

“There are an increasing number of infections for which there are virtually no therapeutic options, and we desperately need new discovery, research and development,” she said.
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!


Volver a “Ideas de negocio”

Ingresar